Document is current
Any future updates will be listed below
-
Authors
Yamashita, Yugo
Morimoto, Takeshi
Amano, Hidewo
Takase, Toru
Hiramori, Seiichi
Kim, Kitae
Oi, Maki
Akao, Masaharu
Kobayashi, Yohei
Toyofuku, Mamoru
Morita, Yusuke
Tada, Tomohisa
Izumi, Toshiaki
Chen, Po-Min
Murata, Koichiro
Tsuyuki, Yoshiaki
Saga, Syunsuke
Nishimoto, Yuji
Sasa, Tomoki
Sakamoto, Jiro
Kinoshita, Minako
Togi, Kiyonori
Mabuchi, Hiroshi
Takabayashi, Kensuke
Yoshikawa, Yusuke
Shiomi, Hiroki
Kato, Takao
Makiyama, Takeru
Ono, Koh
Kimura, Takeshi
,
-
Funding
Funding for this research was provided by:
Research Institute for Production Development
Mitsubishi Tanabe Pharma Corporation
- License Information
-
More Information
Article History
First Online: 29 July 2020
Compliance with ethical standards
:
: Dr. Yamashita received lecture fees from Daiichi-Sankyo, Bristol-Myers Squibb, and Bayer Healthcare. Dr. Morimoto received lecture fees from Mitsubishi Tanabe Pharma and Pfizer Japan and consultant fees from Asahi Kasei, Bristol-Myers Squibb, and Boston Scientific. Dr. Akao received lecture fees from Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Healthcare and Daiichi-Sankyo. Dr. Kimura serves as an advisory board member for Abbott Vascular and Terumo Company. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
: For this type of retrospective study formal consent is not required.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
